The global Radionuclide Drug Conjugate(RDC) market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications.

Radionuclide Drug Conjugate(RDC) are a form of drug designed and developed by coupling precise targeting molecules (monoclonal antibodies or peptides/small molecules, ligands) and powerful killing factors (nuclide, radioisotopes) together with linkers.

From a downstream perspective, Prostate Cancer accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).

Radionuclide Drug Conjugate(RDC) leading manufacturers including Novartis, Telix Pharmaceuticals, Lantheus, Curium, Yuanda Pharmaceuticals, China Tongfang Pharmaceuticals, Dongcheng Pharmaceuticals, Kelun Biotech, Hengrui, Bayer, etc., dominate supply; the top five capture approximately % of global revenue, with Novartis leading 2024 sales at US$ million.

Regional Outlook:

North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).

Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).

Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Radionuclide Drug Conjugate(RDC) market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.

Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation

Scope of Radionuclide Drug Conjugate(RDC) Market Report

Report Metric	Details
Report Name	Radionuclide Drug Conjugate(RDC) Market
Segment by Type	Therapy Diagnosis
Segment by Application	Prostate Cancer Neuroendocrine Cancer Other
Sales by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Novartis, Telix Pharmaceuticals, Lantheus, Curium, Yuanda Pharmaceuticals, China Tongfang Pharmaceuticals, Dongcheng Pharmaceuticals, Kelun Biotech, Hengrui, Bayer, Zhihe Biotechnology, Fulian Pharmaceuticals
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the Radionuclide Drug Conjugate(RDC) study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

Who are the main players in the Radionuclide Drug Conjugate(RDC) Market report?

Ans: The main players in the Radionuclide Drug Conjugate(RDC) Market are Novartis, Telix Pharmaceuticals, Lantheus, Curium, Yuanda Pharmaceuticals, China Tongfang Pharmaceuticals, Dongcheng Pharmaceuticals, Kelun Biotech, Hengrui, Bayer, Zhihe Biotechnology, Fulian Pharmaceuticals

What are the Application segmentation covered in the Radionuclide Drug Conjugate(RDC) Market report?

Ans: The Applications covered in the Radionuclide Drug Conjugate(RDC) Market report are Prostate Cancer, Neuroendocrine Cancer, Other

What are the Type segmentation covered in the Radionuclide Drug Conjugate(RDC) Market report?

Ans: The Types covered in the Radionuclide Drug Conjugate(RDC) Market report are Therapy, Diagnosis

1 Study Coverage

1.1 Introduction to Radionuclide Drug Conjugate(RDC): Definition, Properties, and Key Attributes

1.2 Market Segmentation by Type

1.2.1 Global Radionuclide Drug Conjugate(RDC) Market Size by Type, 2020 VS 2024 VS 2031

1.2.2 Therapy

1.2.3 Diagnosis

1.3 Market Segmentation by Application

1.3.1 Global Radionuclide Drug Conjugate(RDC) Market Size by Application, 2020 VS 2024 VS 2031

1.3.2 Prostate Cancer

1.3.3 Neuroendocrine Cancer

1.3.4 Other

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Radionuclide Drug Conjugate(RDC) Revenue Estimates and Forecasts 2020-2031

2.2 Global Radionuclide Drug Conjugate(RDC) Revenue by Region

2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031

2.2.2 Historical and Forecasted Revenue by Region (2020-2031)

2.2.3 Global Revenue Market Share by Region (2020-2031)

2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competition by Players

3.1 Global Radionuclide Drug Conjugate(RDC) Player Revenue Rankings and Profitability

3.1.1 Global Revenue (Value) by Players (2020-2025)

3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)

3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)

3.1.4 Gross Margin by Top Player (2020 VS 2024)

3.2 Global Radionuclide Drug Conjugate(RDC) Companies Headquarters and Service Footprint

3.3 Main Product Type Market Size by Players

3.3.1 Therapy Market Size by Players

3.3.2 Diagnosis Market Size by Players

3.4 Global Radionuclide Drug Conjugate(RDC) Market Concentration and Dynamics

3.4.1 Global Market Concentration (CR5 and HHI)

3.4.2 Entrant/Exit Impact Analysis

3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Global Product Segmentation Analysis

4.1 Global Radionuclide Drug Conjugate(RDC) Revenue Trends by Type

4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)

4.1.2 Global Revenue Market Share by Type (2020-2031)

4.2 Key Product Attributes and Differentiation

4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk

4.3.1 High-Growth Niches and Adoption Drivers

4.3.2 Profitability Hotspots and Cost Drivers

4.3.3 Substitution Threats

5 Global Downstream Application Analysis

5.1 Global Radionuclide Drug Conjugate(RDC) Revenue by Application

5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)

5.1.2 Revenue Market Share by Application (2020-2031)

5.1.3 High-Growth Application Identification

5.1.4 Emerging Application Case Studies

5.2 Downstream Customer Analysis

5.2.1 Top Customers by Region

5.2.2 Top Customers by Application

6 North America

6.1 North America Market Size (2020-2031)

6.2 North America Key Players Revenue in 2024

6.3 North America Radionuclide Drug Conjugate(RDC) Market Size by Type (2020-2031)

6.4 North America Radionuclide Drug Conjugate(RDC) Market Size by Application (2020-2031)

6.5 North America Growth Accelerators and Market Barriers

6.6 North America Radionuclide Drug Conjugate(RDC) Market Size by Country

6.6.1 North America Revenue Trends by Country

6.6.2 US

6.6.3 Canada

6.6.4 Mexico

7 Europe

7.1 Europe Market Size (2020-2031)

7.2 Europe Key Players Revenue in 2024

7.3 Europe Radionuclide Drug Conjugate(RDC) Market Size by Type (2020-2031)

7.4 Europe Radionuclide Drug Conjugate(RDC) Market Size by Application (2020-2031)

7.5 Europe Growth Accelerators and Market Barriers

7.6 Europe Radionuclide Drug Conjugate(RDC) Market Size by Country

7.6.1 Europe Revenue Trends by Country

7.6.2 Germany

7.6.3 France

7.6.4 U.K.

7.6.5 Italy

7.6.6 Russia

8 Asia-Pacific

8.1 Asia-Pacific Market Size (2020-2031)

8.2 Asia-Pacific Key Players Revenue in 2024

8.3 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Type (2020-2031)

8.4 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Application (2020-2031)

8.5 Asia-Pacific Growth Accelerators and Market Barriers

8.6 Asia-Pacific Radionuclide Drug Conjugate(RDC) Market Size by Region

8.6.1 Asia-Pacific Revenue Trends by Region

8.7 China

8.8 Japan

8.9 South Korea

8.10 Australia

8.11 India

8.12 Southeast Asia

8.12.1 Indonesia

8.12.2 Vietnam

8.12.3 Malaysia

8.12.4 Philippines

8.12.5 Singapore

9 Central and South America

9.1 Central and South America Market Size (2020-2031)

9.2 Central and South America Key Players Revenue in 2024

9.3 Central and South America Radionuclide Drug Conjugate(RDC) Market Size by Type (2020-2031)

9.4 Central and South America Radionuclide Drug Conjugate(RDC) Market Size by Application (2020-2031)

9.5 Central and South America Investment Opportunities and Key Challenges

9.6 Central and South America Radionuclide Drug Conjugate(RDC) Market Size by Country

9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)

9.6.2 Brazil

9.6.3 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Market Size (2020-2031)

10.2 Middle East and Africa Key Players Revenue in 2024

10.3 Middle East and Africa Radionuclide Drug Conjugate(RDC) Market Size by Type (2020-2031)

10.4 Middle East and Africa Radionuclide Drug Conjugate(RDC) Market Size by Application (2020-2031)

10.5 Middle East and Africa Investment Opportunities and Key Challenges

10.6 Middle East and Africa Radionuclide Drug Conjugate(RDC) Market Size by Country

10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)

10.6.2 GCC Countries

10.6.3 Israel

10.6.4 Egypt

10.6.5 South Africa

11 Corporate Profile

11.1 Novartis

11.1.1 Novartis Corporation Information

11.1.2 Novartis Business Overview

11.1.3 Novartis Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.1.4 Novartis Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.1.5 Novartis Radionuclide Drug Conjugate(RDC) Revenue by Product in 2024

11.1.6 Novartis Radionuclide Drug Conjugate(RDC) Revenue by Application in 2024

11.1.7 Novartis Radionuclide Drug Conjugate(RDC) Revenue by Geographic Area in 2024

11.1.8 Novartis Radionuclide Drug Conjugate(RDC) SWOT Analysis

11.1.9 Novartis Recent Developments

11.2 Telix Pharmaceuticals

11.2.1 Telix Pharmaceuticals Corporation Information

11.2.2 Telix Pharmaceuticals Business Overview

11.2.3 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.2.4 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.2.5 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue by Product in 2024

11.2.6 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue by Application in 2024

11.2.7 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue by Geographic Area in 2024

11.2.8 Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) SWOT Analysis

11.2.9 Telix Pharmaceuticals Recent Developments

11.3 Lantheus

11.3.1 Lantheus Corporation Information

11.3.2 Lantheus Business Overview

11.3.3 Lantheus Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.3.4 Lantheus Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.3.5 Lantheus Radionuclide Drug Conjugate(RDC) Revenue by Product in 2024

11.3.6 Lantheus Radionuclide Drug Conjugate(RDC) Revenue by Application in 2024

11.3.7 Lantheus Radionuclide Drug Conjugate(RDC) Revenue by Geographic Area in 2024

11.3.8 Lantheus Radionuclide Drug Conjugate(RDC) SWOT Analysis

11.3.9 Lantheus Recent Developments

11.4 Curium

11.4.1 Curium Corporation Information

11.4.2 Curium Business Overview

11.4.3 Curium Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.4.4 Curium Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.4.5 Curium Radionuclide Drug Conjugate(RDC) Revenue by Product in 2024

11.4.6 Curium Radionuclide Drug Conjugate(RDC) Revenue by Application in 2024

11.4.7 Curium Radionuclide Drug Conjugate(RDC) Revenue by Geographic Area in 2024

11.4.8 Curium Radionuclide Drug Conjugate(RDC) SWOT Analysis

11.4.9 Curium Recent Developments

11.5 Yuanda Pharmaceuticals

11.5.1 Yuanda Pharmaceuticals Corporation Information

11.5.2 Yuanda Pharmaceuticals Business Overview

11.5.3 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.5.4 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.5.5 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue by Product in 2024

11.5.6 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue by Application in 2024

11.5.7 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue by Geographic Area in 2024

11.5.8 Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) SWOT Analysis

11.5.9 Yuanda Pharmaceuticals Recent Developments

11.6 China Tongfang Pharmaceuticals

11.6.1 China Tongfang Pharmaceuticals Corporation Information

11.6.2 China Tongfang Pharmaceuticals Business Overview

11.6.3 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.6.4 China Tongfang Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.6.5 China Tongfang Pharmaceuticals Recent Developments

11.7 Dongcheng Pharmaceuticals

11.7.1 Dongcheng Pharmaceuticals Corporation Information

11.7.2 Dongcheng Pharmaceuticals Business Overview

11.7.3 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.7.4 Dongcheng Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.7.5 Dongcheng Pharmaceuticals Recent Developments

11.8 Kelun Biotech

11.8.1 Kelun Biotech Corporation Information

11.8.2 Kelun Biotech Business Overview

11.8.3 Kelun Biotech Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.8.4 Kelun Biotech Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.8.5 Kelun Biotech Recent Developments

11.9 Hengrui

11.9.1 Hengrui Corporation Information

11.9.2 Hengrui Business Overview

11.9.3 Hengrui Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.9.4 Hengrui Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.9.5 Hengrui Recent Developments

11.10 Bayer

11.10.1 Bayer Corporation Information

11.10.2 Bayer Business Overview

11.10.3 Bayer Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.10.4 Bayer Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.10.5 Company Ten Recent Developments

11.11 Zhihe Biotechnology

11.11.1 Zhihe Biotechnology Corporation Information

11.11.2 Zhihe Biotechnology Business Overview

11.11.3 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.11.4 Zhihe Biotechnology Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.11.5 Zhihe Biotechnology Recent Developments

11.12 Fulian Pharmaceuticals

11.12.1 Fulian Pharmaceuticals Corporation Information

11.12.2 Fulian Pharmaceuticals Business Overview

11.12.3 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Product Features and Attributes

11.12.4 Fulian Pharmaceuticals Radionuclide Drug Conjugate(RDC) Revenue and Gross Margin (2020-2025)

11.12.5 Fulian Pharmaceuticals Recent Developments

12 Radionuclide Drug Conjugate(RDC)Industry Chain Analysis

12.1 Radionuclide Drug Conjugate(RDC) Industry Chain

12.2 Upstream Analysis

12.2.1 Upstream Key Suppliers

12.3 Middlestream Analysis

12.4 Downstream Sales Model and Distribution Networks

12.4.1 Sales Channels

12.4.2 Distributors

13 Radionuclide Drug Conjugate(RDC) Market Dynamics

13.1 Industry Trends and Evolution

13.2 Market Growth Drivers and Emerging Opportunities

13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Radionuclide Drug Conjugate(RDC) Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.1.1 Research Programs/Design

15.1.1.2 Market Size Estimation

15.1.1.3 Market Breakdown and Data Triangulation

15.1.2 Data Source

15.1.2.1 Secondary Sources

15.1.2.2 Primary Sources

15.2 Author Details

FEATURED COMPANIES

Bayer

Bayer AG

Novartis

Telix Pharmaceuticals

Lantheus

Curium

Yuanda Pharmaceuticals

Kelun Biotech

Hengrui

Fulian Pharmaceuticals

China Tongfang Pharmaceuticals

Dongcheng Pharmaceuticals

Zhihe Biotechnology

List of Tables

Table 1. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Radionuclide Drug Conjugate(RDC) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Radionuclide Drug Conjugate(RDC) Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Radionuclide Drug Conjugate(RDC) Revenue by Region (2026-2031) & (US$ Million)

Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 7. Global Radionuclide Drug Conjugate(RDC) Revenue by Players (2020-2025) & (US$ Million)

Table 8. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Players (2020-2025)

Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 10. Global Radionuclide Drug Conjugate(RDC) by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radionuclide Drug Conjugate(RDC) as of 2024)

Table 11. Global Radionuclide Drug Conjugate(RDC) Average Gross Margin (%) by Player (2020 VS 2024)

Table 12. Global Radionuclide Drug Conjugate(RDC) Companies Headquarters

Table 13. Global Radionuclide Drug Conjugate(RDC) Market Concentration Ratio (CR5 and HHI)

Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis

Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 16. Global Radionuclide Drug Conjugate(RDC) Revenue by Type (2020-2025) & (US$ Million)

Table 17. Global Radionuclide Drug Conjugate(RDC) Revenue by Type (2026-2031) & (US$ Million)

Table 18. Key Product Attributes and Differentiation

Table 19. Global Radionuclide Drug Conjugate(RDC) Revenue by Application (2020-2025) & (US$ Million)

Table 20. Global Radionuclide Drug Conjugate(RDC) Revenue by Application (2026-2031) & (US$ Million)

Table 21. Radionuclide Drug Conjugate(RDC) High-Growth Sectors Demand CAGR (2024-2031)

Table 22. Top Customers by Region

Table 23. Top Customers by Application

Table 24. North America Radionuclide Drug Conjugate(RDC) Growth Accelerators and Market Barriers

Table 25. North America Radionuclide Drug Conjugate(RDC) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 26. Europe Radionuclide Drug Conjugate(RDC) Growth Accelerators and Market Barriers

Table 27. Europe Radionuclide Drug Conjugate(RDC) Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. Asia-Pacific Radionuclide Drug Conjugate(RDC) Growth Accelerators and Market Barriers

Table 29. Asia-Pacific Radionuclide Drug Conjugate(RDC) Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 30. Central and South America Radionuclide Drug Conjugate(RDC) Investment Opportunities and Key Challenges

Table 31. Central and South America Radionuclide Drug Conjugate(RDC) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 32. Middle East and Africa Radionuclide Drug Conjugate(RDC) Investment Opportunities and Key Challenges

Table 33. Middle East and Africa Radionuclide Drug Conjugate(RDC) Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 34. Novartis Corporation Information

Table 35. Novartis Description and Major Businesses

Table 36. Novartis Product Features and Attributes

Table 37. Novartis Revenue (US$ Million) and Gross Margin (2020-2025)

Table 38. Novartis Revenue Proportion by Product in 2024

Table 39. Novartis Revenue Proportion by Application in 2024

Table 40. Novartis Revenue Proportion by Geographic Area in 2024

Table 41. Novartis Radionuclide Drug Conjugate(RDC) SWOT Analysis

Table 42. Novartis Recent Developments

Table 43. Telix Pharmaceuticals Corporation Information

Table 44. Telix Pharmaceuticals Description and Major Businesses

Table 45. Telix Pharmaceuticals Product Features and Attributes

Table 46. Telix Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)

Table 47. Telix Pharmaceuticals Revenue Proportion by Product in 2024

Table 48. Telix Pharmaceuticals Revenue Proportion by Application in 2024

Table 49. Telix Pharmaceuticals Revenue Proportion by Geographic Area in 2024

Table 50. Telix Pharmaceuticals Radionuclide Drug Conjugate(RDC) SWOT Analysis

Table 51. Telix Pharmaceuticals Recent Developments

Table 52. Lantheus Corporation Information

Table 53. Lantheus Description and Major Businesses

Table 54. Lantheus Product Features and Attributes

Table 55. Lantheus Revenue (US$ Million) and Gross Margin (2020-2025)

Table 56. Lantheus Revenue Proportion by Product in 2024

Table 57. Lantheus Revenue Proportion by Application in 2024

Table 58. Lantheus Revenue Proportion by Geographic Area in 2024

Table 59. Lantheus Radionuclide Drug Conjugate(RDC) SWOT Analysis

Table 60. Lantheus Recent Developments

Table 61. Curium Corporation Information

Table 62. Curium Description and Major Businesses

Table 63. Curium Product Features and Attributes

Table 64. Curium Revenue (US$ Million) and Gross Margin (2020-2025)

Table 65. Curium Revenue Proportion by Product in 2024

Table 66. Curium Revenue Proportion by Application in 2024

Table 67. Curium Revenue Proportion by Geographic Area in 2024

Table 68. Curium Radionuclide Drug Conjugate(RDC) SWOT Analysis

Table 69. Curium Recent Developments

Table 70. Yuanda Pharmaceuticals Corporation Information

Table 71. Yuanda Pharmaceuticals Description and Major Businesses

Table 72. Yuanda Pharmaceuticals Product Features and Attributes

Table 73. Yuanda Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)

Table 74. Yuanda Pharmaceuticals Revenue Proportion by Product in 2024

Table 75. Yuanda Pharmaceuticals Revenue Proportion by Application in 2024

Table 76. Yuanda Pharmaceuticals Revenue Proportion by Geographic Area in 2024

Table 77. Yuanda Pharmaceuticals Radionuclide Drug Conjugate(RDC) SWOT Analysis

Table 78. Yuanda Pharmaceuticals Recent Developments

Table 79. China Tongfang Pharmaceuticals Corporation Information

Table 80. China Tongfang Pharmaceuticals Description and Major Businesses

Table 81. China Tongfang Pharmaceuticals Product Features and Attributes

Table 82. China Tongfang Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)

Table 83. China Tongfang Pharmaceuticals Recent Developments

Table 84. Dongcheng Pharmaceuticals Corporation Information

Table 85. Dongcheng Pharmaceuticals Description and Major Businesses

Table 86. Dongcheng Pharmaceuticals Product Features and Attributes

Table 87. Dongcheng Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)

Table 88. Dongcheng Pharmaceuticals Recent Developments

Table 89. Kelun Biotech Corporation Information

Table 90. Kelun Biotech Description and Major Businesses

Table 91. Kelun Biotech Product Features and Attributes

Table 92. Kelun Biotech Revenue (US$ Million) and Gross Margin (2020-2025)

Table 93. Kelun Biotech Recent Developments

Table 94. Hengrui Corporation Information

Table 95. Hengrui Description and Major Businesses

Table 96. Hengrui Product Features and Attributes

Table 97. Hengrui Revenue (US$ Million) and Gross Margin (2020-2025)

Table 98. Hengrui Recent Developments

Table 99. Bayer Corporation Information

Table 100. Bayer Description and Major Businesses

Table 101. Bayer Product Features and Attributes

Table 102. Bayer Revenue (US$ Million) and Gross Margin (2020-2025)

Table 103. Bayer Recent Developments

Table 104. Zhihe Biotechnology Corporation Information

Table 105. Zhihe Biotechnology Description and Major Businesses

Table 106. Zhihe Biotechnology Product Features and Attributes

Table 107. Zhihe Biotechnology Revenue (US$ Million) and Gross Margin (2020-2025)

Table 108. Zhihe Biotechnology Recent Developments

Table 109. Fulian Pharmaceuticals Corporation Information

Table 110. Fulian Pharmaceuticals Description and Major Businesses

Table 111. Fulian Pharmaceuticals Product Features and Attributes

Table 112. Fulian Pharmaceuticals Revenue (US$ Million) and Gross Margin (2020-2025)

Table 113. Fulian Pharmaceuticals Recent Developments

Table 114. Raw Materials Key Suppliers

Table 115. Distributors List

Table 116. Market Trends and Market Evolution

Table 117. Market Drivers and Opportunities

Table 118. Market Challenges, Risks, and Restraints

Table 119. Research Programs/Design for This Report

Table 120. Key Data Information from Secondary Sources

Table 121. Key Data Information from Primary Sources

List of Figures

Figure 1. Radionuclide Drug Conjugate(RDC) Product Picture

Figure 2. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Therapy Product Picture

Figure 4. Diagnosis Product Picture

Figure 5. Global Radionuclide Drug Conjugate(RDC) Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 6. Prostate Cancer

Figure 7. Neuroendocrine Cancer

Figure 8. Other

Figure 9. Radionuclide Drug Conjugate(RDC) Report Years Considered

Figure 10. Global Radionuclide Drug Conjugate(RDC) Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 12. Global Radionuclide Drug Conjugate(RDC) Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 13. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Region (2020-2031)

Figure 14. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share Ranking (2024)

Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 16. Therapy Revenue Market Share by Player in 2024

Figure 17. Diagnosis Revenue Market Share by Player in 2024

Figure 18. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Type (2020-2031)

Figure 19. Global Radionuclide Drug Conjugate(RDC) Revenue Market Share by Application (2020-2031)

Figure 20. North America Radionuclide Drug Conjugate(RDC) Revenue YoY (2020-2031) & (US$ Million)

Figure 21. North America Top 5 Players Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) in 2024

Figure 22. North America Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) by Type (2020 - 2031)

Figure 23. North America Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) by Application (2020-2031)

Figure 24. US Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 25. Canada Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 26. Mexico Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 27. Europe Radionuclide Drug Conjugate(RDC) Revenue YoY (2020-2031) & (US$ Million)

Figure 28. Europe Top 5 Players Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) in 2024

Figure 29. Europe Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) by Type (2020-2031)

Figure 30. Europe Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) by Application (2020-2031)

Figure 31. Germany Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 32. France Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 33. U.K. Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 34. Italy Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 35. Russia Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 36. Asia-Pacific Radionuclide Drug Conjugate(RDC) Revenue YoY (2020-2031) & (US$ Million)

Figure 37. Asia-Pacific Top 8 Players Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) in 2024

Figure 38. Asia-Pacific Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) by Type (2020-2031)

Figure 39. Asia-Pacific Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) by Application (2020-2031)

Figure 40. Indonesia Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 41. Japan Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 42. South Korea Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 43. Australia Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 44. India Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 45. Indonesia Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 46. Vietnam Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 47. Malaysia Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 48. Philippines Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 49. Singapore Radionuclide Drug Conjugate(RDC) Revenue (2020-2031) & (US$ Million)

Figure 50. Central and South America Radionuclide Drug Conjugate(RDC) Revenue YoY (2020-2031) & (US$ Million)

Figure 51. Central and South America Top 5 Players Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) in 2024

Figure 52. Central and South America Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) by Type (2020-2031)

Figure 53. Central and South America Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) by Application (2020-2031)

Figure 54. Brazil Radionuclide Drug Conjugate(RDC) Revenue (2020-2025) & (US$ Million)

Figure 55. Argentina Radionuclide Drug Conjugate(RDC) Revenue (2020-2025) & (US$ Million)

Figure 56. Middle East and Africa Radionuclide Drug Conjugate(RDC) Revenue YoY (2020-2031) & (US$ Million)

Figure 57. Middle East and Africa Top 5 Players Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) in 2024

Figure 58. South America Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) by Type (2020-2031)

Figure 59. Middle East and Africa Radionuclide Drug Conjugate(RDC) Revenue (US$ Million) by Application (2020-2031)

Figure 60. GCC Countries Radionuclide Drug Conjugate(RDC) Revenue (2020-2025) & (US$ Million)

Figure 61. Israel Radionuclide Drug Conjugate(RDC) Revenue (2020-2025) & (US$ Million)

Figure 62. Egypt Radionuclide Drug Conjugate(RDC) Revenue (2020-2025) & (US$ Million)

Figure 63. South Africa Radionuclide Drug Conjugate(RDC) Revenue (2020-2025) & (US$ Million)

Figure 64. Radionuclide Drug Conjugate(RDC) Industry Chain Mapping

Figure 65. Channels of Distribution (Direct Vs Distribution)

Figure 66. Bottom-up and Top-down Approaches for This Report

Figure 67. Data Triangulation

Figure 68. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

120 Pages

Type: Report

Code: QYRE-Auto-5A18047

Thu Oct 23 00:00:00 UTC 2025

Add to Cart

Global Gimeracil Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-32E17373

Thu Oct 23 00:00:00 UTC 2025

Add to Cart

Global Boron Citrate Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-16B17392

Thu Oct 23 00:00:00 UTC 2025

Add to Cart

Global Lidocaine Spray Market Outlook, In‑Depth Analysis & Forecast to 2031

120 Pages

Type: Report

Code: QYRE-Auto-28Q17233

Thu Oct 23 00:00:00 UTC 2025

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Radionuclide Drug Conjugate(RDC) Market Outlook, In‑Depth Analysis & Forecast to 2031

Published Date: October 2025

Report Code: QYRE-Auto-3Z20104

Global Radionuclide Drug Conjugate(RDC) Market Outlook, In‑Depth Analysis & Forecast to 2031

FEATURED COMPANIES

Radionuclide Drug Conjugate(RDC) Market

Report Includes:

Scope of Radionuclide Drug Conjugate(RDC) Market Report

Chapter Outline

FAQ for this report

Who are the main players in the Radionuclide Drug Conjugate(RDC) Market report?

What are the Application segmentation covered in the Radionuclide Drug Conjugate(RDC) Market report?

What are the Type segmentation covered in the Radionuclide Drug Conjugate(RDC) Market report?

FEATURED COMPANIES

RELATED REPORTS